271 related articles for article (PubMed ID: 30606315)
1. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa.
Kim HY; Hanrahan CF; Martinson N; Golub JE; Dowdy DW
Int J Tuberc Lung Dis; 2018 Dec; 22(12):1435-1442. PubMed ID: 30606315
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India.
Kapoor S; Gupta A; Shah M
Int J Tuberc Lung Dis; 2016 Jan; 20(1):85-92. PubMed ID: 26688533
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of tuberculosis screening and isoniazid treatment in the TB/HIV in Rio (THRio) Study.
Azadi M; Bishai DM; Dowdy DW; Moulton LH; Cavalcante S; Saraceni V; Pacheco AG; Cohn S; Chaisson RE; Durovni B; Golub JE
Int J Tuberc Lung Dis; 2014 Dec; 18(12):1443-8. PubMed ID: 25517809
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of including tuberculin skin testing in an IPT program for HIV-infected persons in Uganda.
Shrestha RK; Mugisha B; Bunnell R; Mermin J; Hitimana-Lukanika C; Odeke R; Madra P; Adatu F; Blandford JM
Int J Tuberc Lung Dis; 2006 Jun; 10(6):656-62. PubMed ID: 16776453
[TBL] [Abstract][Full Text] [Related]
5. QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients.
Khawcharoenporn T; Phetsuksiri B; Rudeeaneksin J; Srisungngam S; Apisarnthanarak A
Jpn J Infect Dis; 2017 Sep; 70(5):502-506. PubMed ID: 28367883
[TBL] [Abstract][Full Text] [Related]
6. Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV.
Weinberg A; Aaron L; Montepiedra G; Sterling TR; Browning R; Mmbaga B; Vhembo T; Naik S; Kabugho E; Masheto G; Pahwa S; Mathad JS; LaCourse SM; McCarthy K; Bradford S; Theron G; Costello D; Zimmer B; Pierre MF; Gausi K; Denti P; Haas DW; Gupta A;
Clin Infect Dis; 2021 Nov; 73(9):e3555-e3562. PubMed ID: 32720695
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
Shayo GA; Chitama D; Moshiro C; Aboud S; Bakari M; Mugusi F
BMC Public Health; 2017 Jul; 18(1):35. PubMed ID: 28724374
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Johnson KT; Churchyard GJ; Sohn H; Dowdy DW
Clin Infect Dis; 2018 Sep; 67(7):1072-1078. PubMed ID: 29617965
[TBL] [Abstract][Full Text] [Related]
9. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting.
Mandalakas AM; Hesseling AC; Gie RP; Schaaf HS; Marais BJ; Sinanovic E
Thorax; 2013 Mar; 68(3):247-55. PubMed ID: 22717944
[TBL] [Abstract][Full Text] [Related]
10. Inequality in uptake of isoniazid prevention therapy and Mantoux test among pregnant women with HIV in the Eastern Cape, South Africa.
Adeniyi OV; Selanto-Chairman N; Owolabi EO; Ajayi AI; Kayembe DK; Ter Goon D; Gordana A; Lambert J
BMC Public Health; 2019 Oct; 19(1):1407. PubMed ID: 31664978
[TBL] [Abstract][Full Text] [Related]
11. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana.
Smith T; Samandari T; Abimbola T; Marston B; Sangrujee N
J Acquir Immune Defic Syndr; 2015 Nov; 70(3):e84-93. PubMed ID: 26258564
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model.
Tasillo A; Salomon JA; Trikalinos TA; Horsburgh CR; Marks SM; Linas BP
JAMA Intern Med; 2017 Dec; 177(12):1755-1764. PubMed ID: 29049814
[TBL] [Abstract][Full Text] [Related]
13. Relevance and acceptability of using the Quantiferon gold test (QGIT) to screen CD4 blood draws for latent TB infection among PLHIV in South Africa: formative qualitative research findings from the TEKO trial.
Kerrigan D; Tudor C; Motlhaoleng K; Lebina L; Qomfu C; Variava E; Chon S; Martinson N; Golub JE
BMC Health Serv Res; 2018 Apr; 18(1):288. PubMed ID: 29661197
[TBL] [Abstract][Full Text] [Related]
14. The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia.
Sutton BS; Arias MS; Chheng P; Eang MT; Kimerling ME
Int J Tuberc Lung Dis; 2009 Jun; 13(6):713-8. PubMed ID: 19460246
[TBL] [Abstract][Full Text] [Related]
15. Enhanced cost-benefit analysis of strategies for LTBI screening and INH chemoprevention in Germany.
Diel R; Schaberg T; Loddenkemper R; Welte T; Nienhaus A
Respir Med; 2009 Dec; 103(12):1838-53. PubMed ID: 19682884
[TBL] [Abstract][Full Text] [Related]
16. Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients.
Khawcharoenporn T; Apisarnthanarak A; Manosuthi W; Sungkanuparph S; Mundy LM
Int J Tuberc Lung Dis; 2012; 16(3):336-41. PubMed ID: 22230143
[TBL] [Abstract][Full Text] [Related]
17. Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study.
Biraro IA; Egesa M; Kimuda S; Smith SG; Toulza F; Levin J; Joloba M; Katamba A; Cose S; Dockrell HM; Elliott AM
BMC Infect Dis; 2015 Oct; 15():438. PubMed ID: 26493989
[TBL] [Abstract][Full Text] [Related]
18. Tuberculin skin test reversion following isoniazid preventive therapy reflects diversity of immune response to primary Mycobacterium tuberculosis infection.
Johnson DF; Malone LL; Zalwango S; Mukisa Oketcho J; Chervenak KA; Thiel B; Mayanja-Kizza H; Stein CM; Boom WH; Lancioni CL;
PLoS One; 2014; 9(5):e96613. PubMed ID: 24796677
[TBL] [Abstract][Full Text] [Related]
19. Contact evaluation and isoniazid preventive therapy among close and household contacts of tuberculosis patients in Lima, Peru: an analysis of routine data.
Otero L; Battaglioli T; Ríos J; De la Torre Z; Trocones N; Ordoñez C; Seas C; Van der Stuyft P
Trop Med Int Health; 2020 Mar; 25(3):346-356. PubMed ID: 31758837
[TBL] [Abstract][Full Text] [Related]
20. Health system barriers to implementation of TB preventive strategies in South African primary care facilities.
Van Ginderdeuren E; Bassett J; Hanrahan C; Mutunga L; Van Rie A
PLoS One; 2019; 14(2):e0212035. PubMed ID: 30763378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
